ABSTRACT BACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established.
C ardiovascular disease is the leading cause of death in China, accounting for 41% of all deaths (1, 2) . Exponential increases in percutaneous coronary intervention (PCI) in China have been observed over the last 10 years (2), with approximately 450,000 PCI cases performed in 2013 (3) . The everolimus-eluting bioresorbable vascular scaffold (BVS) (Absorb, Abbott Vascular, Santa Clara, California) offers a new PCI option for this growing patient population.
The BVS is constructed from a poly L-lactide backbone coated with a bioresorbable polymeric poly (D,L-lactide) layer containing everolimus, and it was designed to provide comparable radial strength and antirestenotic efficacy to metallic drug-eluting stents (DES) in the first year. The degradation of poly L-lactide in vivo is governed by bulk erosion beginning with a decline in molecular weight, followed by mass loss via hydrolysis upon exposure to water over time (4, 5) . Complete bioresorption at approximately The ABSORB China Trial index procedure was required. The P2Y 12 inhibitor loading dose could be omitted if the patient was on chronic clopidogrel or ticagrelor therapy ($3 days), unless an acute coronary syndrome was present.
Following PCI, aspirin 100 mg daily for at least 5 years was prescribed, with clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) for a minimum of 12 months. Prasugrel was not available for use during this study.
Clinical follow-up was planned at 30 days, 6 months, 9 months, and at 1, 2, 3, 4, and 5 years postprocedure. Routine follow-up angiography was planned in all patients at 1 year (AE28 days). CoCr-EES). Subject disposition is shown in Figure 1 .
Five patients withdrew consent before use of any study device. Four crossovers occurred, 2 in each group. One crossover from BVS to CoCr-EES occurred after the BVS failed to cross the target lesion, and the other was due to absence of the appropriate BVS device size at the time of randomization. The 2 crossovers from CoCr-EES to BVS were due to site error. Of the 480 patients in the ITT population, 20 did not meet PTE criteria: 5 were subject withdrawals before any study device attempts during the index procedure (3 BVS and 2 CoCr-EES); 13 were subjects with at least 1 pre-specified protocol deviation (9 BVS and 4 Table 2) . Device diameters and length were also similar between groups. Use of intravascular imaging was infrequent. Device post-dilation was performed in a slightly greater proportion of BVS cases. Acute device and procedural success rates were similar with BVS and CoCr-EES, as was discharge medication use ( Table 2) .
Baseline lesion length, reference vessel diameter, MLD, and %DS were balanced between groups ( Table 3) . The post-procedure in-segment MLD, acute gain, and %DS were similar with both devices. However, within the device the post-procedural MLD and acute gain were lower with BVS compared with CoCr-EES, and the %DS was slightly greater. As shown in Table 5 and Figure 2 , Values are mean AE SD or % (n/N) unless otherwise indicated. *No other intravascular imaging devices were used. Table 1 . Values are least square mean AE SE unless otherwise indicated. Results of all analyses are adjusted using generalized estimating equations for cases in which 2 lesions were present in a single patient.
CI ¼ confidence interval; other abbreviations as in
ABR ¼ angiographic binary restenosis; DS ¼ diameter stenosis; LL ¼ late loss; MLD ¼ minimum lumen diameter; RVD ¼ reference vessel diameter; other abbreviations as in Tables 1 and 2. Gao et al. Values are % (n/N) unless otherwise indicated. *The 2-sided p value based on Pearson's chi-square test was used when Cochran's rule was met; otherwise, the Fisher exact test was used. †The end of the 1-year follow-up window was 393 days. The denominators exclude subjects who were lost to follow-up or terminated during each specific time interval in whom no DMR event had occurred. ‡The denominators exclude subjects who were lost to follow-up or terminated during each specific time interval in whom no specific ST event had occurred.
DMR ¼ all-cause death, myocardial infarction, or any revascularization; DoCE ¼ device-oriented composite endpoint; ID ¼ ischemia driven; MACE ¼ major adverse cardiac events (cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization); MI ¼ myocardial infarction; PoCE ¼ patient-oriented composite endpoint; TLF ¼ target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization); TVF ¼ target vessel failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target vessel revascularization); TLR ¼ target lesion revascularization; TV-MI ¼ target vessel myocardial infarction; TVR ¼ target vessel revascularization; other abbreviations as in Tables 1 and 2. Gao et al. in-device and -segment ABR (2.9% and 3.9%, respectively) and 1-year ID-TLR (2.5%), comparable to the rates of in-device and -segment ABR (0.8% and 2.8%, respectively) and ID-TLR (2.1%) observed with CoCr-EES.
The first-generation BVS has thicker struts and a larger crossing profile than contemporary metallic DES. Nevertheless, issues with deliverability and tracking of BVS were not observed in the present study, with high rates of acute device and procedural success achieved in the present and prior ABSORB studies, comparable to CoCr-EES in noncomplex lesions (8, 16) . Aggressive pre-dilation was recommended, and post-dilation was performed at a higher rate with BVS than CoCr-EES, which may have helped achieve high rates of acute procedural success with only a 2.0% bailout rate. Nonetheless, improvements in implantation technique (e.g., routine post-dilation or more frequent use of intravascular imaging guidance, which was rarely used in the present study) and device iterations (thinner struts with reduced recoil) may further improve deliverability and angiographic and clinical outcomes, especially in complex lesions.
In the present study, the 1-year rates of deviceand patient-oriented composite outcomes were comparable between BVS and CoCr-EES. Similar results were reported from the ABSORB II European multicenter randomized trial (8) . Acknowledging 
